vs
Everus Construction Group, Inc.（ECG）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Everus Construction Group, Inc.的季度营收约是Royalty Pharma plc的1.6倍（$1.0B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 5.5%，领先29.0%），Everus Construction Group, Inc.同比增速更快（33.2% vs 4.8%），过去两年Everus Construction Group, Inc.的营收复合增速更高（27.1% vs 4.6%）
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ECG vs RPRX — 直观对比
营收规模更大
ECG
是对方的1.6倍
$622.0M
营收增速更快
ECG
高出28.4%
4.8%
净利率更高
RPRX
高出29.0%
5.5%
两年增速更快
ECG
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $622.0M |
| 净利润 | $55.3M | $214.2M |
| 毛利率 | 11.6% | — |
| 营业利润率 | 6.8% | 62.4% |
| 净利率 | 5.5% | 34.4% |
| 营收同比 | 33.2% | 4.8% |
| 净利润同比 | 60.4% | 2.9% |
| 每股收益（稀释后） | $1.09 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ECGRPRX
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $986.8M | $609.3M | ||
| Q2 25 | $921.5M | $578.7M | ||
| Q1 25 | $826.6M | $568.2M | ||
| Q4 24 | $759.6M | $593.6M | ||
| Q3 24 | $761.0M | $564.7M | ||
| Q2 24 | $703.4M | $537.3M | ||
| Q1 24 | $625.7M | $568.0M |
净利润ECGRPRX
| Q4 25 | $55.3M | $214.2M | ||
| Q3 25 | $57.0M | $288.2M | ||
| Q2 25 | $52.8M | $30.2M | ||
| Q1 25 | $36.7M | $238.3M | ||
| Q4 24 | $34.5M | $208.2M | ||
| Q3 24 | $41.8M | $544.0M | ||
| Q2 24 | $39.0M | $102.0M | ||
| Q1 24 | $28.2M | $4.8M |
毛利率ECGRPRX
| Q4 25 | 11.6% | — | ||
| Q3 25 | 12.6% | — | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 11.8% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 11.9% | — |
营业利润率ECGRPRX
| Q4 25 | 6.8% | 62.4% | ||
| Q3 25 | 7.3% | 70.1% | ||
| Q2 25 | 7.9% | 36.3% | ||
| Q1 25 | 6.2% | 94.0% | ||
| Q4 24 | 6.1% | 60.9% | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 7.3% | 50.2% | ||
| Q1 24 | 6.2% | -13.0% |
净利率ECGRPRX
| Q4 25 | 5.5% | 34.4% | ||
| Q3 25 | 5.8% | 47.3% | ||
| Q2 25 | 5.7% | 5.2% | ||
| Q1 25 | 4.4% | 41.9% | ||
| Q4 24 | 4.5% | 35.1% | ||
| Q3 24 | 5.5% | 96.3% | ||
| Q2 24 | 5.5% | 19.0% | ||
| Q1 24 | 4.5% | 0.8% |
每股收益（稀释后）ECGRPRX
| Q4 25 | $1.09 | $0.49 | ||
| Q3 25 | $1.11 | $0.67 | ||
| Q2 25 | $1.03 | $0.07 | ||
| Q1 25 | $0.72 | $0.55 | ||
| Q4 24 | $0.68 | $0.46 | ||
| Q3 24 | $0.82 | $1.21 | ||
| Q2 24 | $0.76 | $0.23 | ||
| Q1 24 | $0.55 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $281.5M | $9.0B |
| 股东权益账面价值 | $629.8M | $9.7B |
| 总资产 | $1.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.45× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ECGRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $553.0K | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务ECGRPRX
| Q4 25 | $281.5M | $9.0B | ||
| Q3 25 | $285.1M | $8.9B | ||
| Q2 25 | $288.6M | $8.0B | ||
| Q1 25 | $292.1M | $7.6B | ||
| Q4 24 | $295.6M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ECGRPRX
| Q4 25 | $629.8M | $9.7B | ||
| Q3 25 | $573.0M | $9.6B | ||
| Q2 25 | $514.4M | $9.5B | ||
| Q1 25 | $460.2M | $9.8B | ||
| Q4 24 | $422.6M | $10.3B | ||
| Q3 24 | $453.3M | $10.3B | ||
| Q2 24 | $490.0M | $9.8B | ||
| Q1 24 | $464.3M | $9.9B |
总资产ECGRPRX
| Q4 25 | $1.7B | $19.6B | ||
| Q3 25 | $1.6B | $19.3B | ||
| Q2 25 | $1.5B | $18.3B | ||
| Q1 25 | $1.4B | $17.6B | ||
| Q4 24 | $1.3B | $18.2B | ||
| Q3 24 | $1.3B | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比ECGRPRX
| Q4 25 | 0.45× | 0.92× | ||
| Q3 25 | 0.50× | 0.93× | ||
| Q2 25 | 0.56× | 0.84× | ||
| Q1 25 | 0.63× | 0.78× | ||
| Q4 24 | 0.70× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $23.5M | — |
| 自由现金流率自由现金流/营收 | 2.3% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 0.87× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $90.0M | — |
8季度趋势，按日历期对齐
经营现金流ECGRPRX
| Q4 25 | $48.2M | $827.1M | ||
| Q3 25 | $76.2M | $702.6M | ||
| Q2 25 | $25.3M | $364.0M | ||
| Q1 25 | $7.1M | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $78.9M | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | $21.9M | $664.6M |
自由现金流ECGRPRX
| Q4 25 | $23.5M | — | ||
| Q3 25 | $65.7M | — | ||
| Q2 25 | $12.3M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $60.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $12.6M | — |
自由现金流率ECGRPRX
| Q4 25 | 2.3% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | -1.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.0% | — |
资本支出强度ECGRPRX
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.5% | — |
现金转化率ECGRPRX
| Q4 25 | 0.87× | 3.86× | ||
| Q3 25 | 1.34× | 2.44× | ||
| Q2 25 | 0.48× | 12.06× | ||
| Q1 25 | 0.19× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.89× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 0.77× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ECG
| Commercial | $594.5M | 59% |
| Utility | $203.5M | 20% |
| Industrial | $82.8M | 8% |
| Institutional | $66.1M | 7% |
| Service And Other | $28.4M | 3% |
| Transportation | $24.2M | 2% |
| Renewables | $19.8M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
